Mapping Array Libraries Sample Clauses

Mapping Array Libraries. In partial consideration of the delivery of up to ten (10) Mapping Array Libraries during the Research Period in accordance with Section 3.3, Solvay shall pay ArQule an annual fee in the amount of three hundred thousand dollars ($300,000), payable as follows: $150,000 On the Effective Date $150,000 On January 2, 2002 Solvay may obtain access to additional available Mapping Array Libraries during the Research Period at a cost of fifty thousand dollars ($50,000) per Mapping Array Library which amount shall be paid to ArQule within thirty (30) days of shipment.
Sample 1
AutoNDA by SimpleDocs
Mapping Array Libraries. In partial consideration of the delivery of up to [*****] Mapping Array Libraries during the Research Period in accordance with Section 3.3, Solvay shall pay ArQule an annual fee in the amount of [*****], payable as follows: [*****] Solvay may obtain access to additional available Mapping Array Libraries during the Research Period at a cost of [*****] per Mapping Array Library which amount shall be paid to ArQule within thirty (30) days of shipment.
Sample 1
Mapping Array Libraries. The Mapping Array repository is a diverse screening library. The Mapping Array Libraries produced in the year 2000 contain approximately 200,000 compounds. The Mapping Array Libraries planned for production in the year 2001 will contain approximately 200,000 compounds. ArQule will provide 1 mg of each Mapping Array compound dissolved in 250(mu)L of 10mM 100% DMSO. The compounds will be provided in 96-well plates with up to 80 filled wells per plate. ArQule performs 25% quality control analysis of each Xxxxing Array Library by HPLC/UV/ELSD for purity and flow injection mass spectrometry for confirmation of molecular weight. Each Mapping Array Library is on average more than 85% pure as determined by HPLC analysis. A Markush structure file defining each chemical theme is supplied with every shipment.
Sample 1

Related to Mapping Array Libraries

  • Research Records Each Party shall maintain records of each Research Program (or cause such records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved by or on behalf of such Party in the performance of such Research Program. All laboratory notebooks shall be maintained for no less than [***].

  • Interfaces 1 2 wire i/f (towards PSTN) -------------------------------------------------------------------------------------------------------- 2 2 wire i/f (towards standard handset) -------------------------------------------------------------------------------------------------------- 2.2 FUNCTIONS -------------------------------------------------------------------------------------------------------- 1 Selective Call -------------------------------------------------------------------------------------------------------- 2 Conference Call (up to four participants) ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- 3 MANAGEMENT COMMUNICATION -------------------------------------------------------------------------------------------------------- 3.1 COMMUNICATION INTERFACES see OPTera Product Description SEC. 5.2.3 - Standard Communications Interfaces and SEC.7.3 - Management Communication -------------------------------------------------------------------------------------------------------- 1 F- Interface (RS 232) -------------------------------------------------------------------------------------------------------- 2 Q- interface as gateway to the EMS -------------------------------------------------------------------------------------------------------- 3 Qecc Routing (2 level IS-IS) -------------------------------------------------------------------------------------------------------- 4 Q I/F (Ethernet) -------------------------------------------------------------------------------------------------------- 5 Optical Supervisory Channel ----------------------------------------------------------------------------------------------------------------------------------- 6 OSC - wavelength IR IR IR see OPTera Product - bitrate Description SEC. 5.2.2 - optical span limit - Per Wavelength - transmission protocol Optical Service Channel and SEC.7.3 - Management Communication ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- 3.2 O & M INTERFACES ----------------------------------------------------------------------------------------------------------------------------------- 1 8 x Remote Control Inputs ----------------------------------------------------------------------------------------------------------------------------------- 2 Remote Control Outputs ----------------------------------------------------------------------------------------------------------------------------------- 3 Card LED support ----------------------------------------------------------------------------------------------------------------------------------- 4 Subrack LED support ----------------------------------------------------------------------------------------------------------------------------------- 5 Rack Alarm support ----------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------

  • Know-How The term “

  • Research Analyst Independence The Company acknowledges that the Underwriters’ research analysts and research departments are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriters’ research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of their respective investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriters’ investment banking divisions. The Company acknowledges that each of the Underwriters is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.

  • Field The term “

  • Research Independence The Company acknowledges that each Underwriter’s research analysts and research departments, if any, are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriter’s research analysts may hold and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriter’s investment banking divisions. The Company acknowledges that the Representative is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or equity securities of the Company.

  • Development Records Each Party shall maintain complete, current and accurate records of all Development activities conducted by it hereunder, and all data and other information resulting from such activities. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes. Each Party shall document all non-clinical studies and Clinical Trials in formal written study reports according to Applicable Laws and national and international guidelines (e.g., ICH, cGCP, cGLP, and cGMP).

  • Investment Analysis and Implementation In carrying out its obligations under Section 1 hereof, the Advisor shall:

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Supply of Materials Unless the parties otherwise agree in a Work Order, Manufacturer will supply, in accordance with the relevant approved raw material specifications, all materials to be used by Manufacturer in the performance of Services under a Work Order other than the Rhythm Materials specified in such Work Order. Rhythm or its designees will provide Manufacturer with the Rhythm Materials. Manufacturer agrees (a) to account for all Rhythm Materials, (b) not to provide Rhythm Materials to any third party (other than an Affiliate acting as a permitted subcontractor) without the express prior written consent of Rhythm, (c) not to use Rhythm Materials for any purpose other than conducting the Services, including, without limitation, not to analyze, characterize, modify or reverse engineer any Rhythm Materials or take any action to determine the structure or composition of any Rhythm Materials unless required * CONFIDENTIAL TREATMENT REQUESTED. OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. pursuant to a signed Work Order, and (d) to destroy or return to Rhythm all unused quantities of Rhythm Materials according to Rhythm’s written directions.

Time is Money Join Law Insider Premium to draft better contracts faster.